Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,507 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Effect of Viloxazine Extended-Release Capsules on Functional Impairments Associated with Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents in Four Phase 3 Placebo-Controlled Trials.
Nasser A, Hull JT, Liranso T, Busse GD, Melyan Z, Childress AC, A Lopez F, Rubin J. Nasser A, et al. Among authors: rubin j. Neuropsychiatr Dis Treat. 2021 Jun 3;17:1751-1762. doi: 10.2147/NDT.S312011. eCollection 2021. Neuropsychiatr Dis Treat. 2021. PMID: 34113106 Free PMC article.
Translating Attention-Deficit/Hyperactivity Disorder Rating Scale-5 and Weiss Functional Impairment Rating Scale-Parent Effectiveness Scores into Clinical Global Impressions Clinical Significance Levels in Four Randomized Clinical Trials of SPN-812 (Viloxazine Extended-Release) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.
Nasser A, Kosheleff AR, Hull JT, Liranso T, Qin P, Busse GD, O'Neal W, Fava M, Faraone SV, Rubin J. Nasser A, et al. Among authors: rubin j. J Child Adolesc Psychopharmacol. 2021 Apr;31(3):214-226. doi: 10.1089/cap.2020.0148. Epub 2021 Feb 17. J Child Adolesc Psychopharmacol. 2021. PMID: 33600233 Free PMC article. Clinical Trial.
Executive Function Outcome of Treatment with Viloxazine Extended-Release Capsules in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Post-Hoc Analysis of Four Randomized Clinical Trials.
Faraone SV, Gomeni R, Hull JT, Busse GD, Melyan Z, Rubin J, Nasser A. Faraone SV, et al. Among authors: rubin j. Paediatr Drugs. 2021 Nov;23(6):583-589. doi: 10.1007/s40272-021-00470-2. Epub 2021 Sep 15. Paediatr Drugs. 2021. PMID: 34523063 Free PMC article.
A post hoc analysis of the effect of viloxazine extended-release capsules on learning and school problems in children and adolescents with attention-deficit/hyperactivity disorder.
Faraone SV, Gomeni R, Hull JT, Busse GD, Melyan Z, Rubin J, Nasser A. Faraone SV, et al. Among authors: rubin j. Eur Child Adolesc Psychiatry. 2023 Mar;32(3):491-499. doi: 10.1007/s00787-021-01877-5. Epub 2021 Sep 28. Eur Child Adolesc Psychiatry. 2023. PMID: 34581911 Free PMC article. Clinical Trial.
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder.
Nasser A, Hull JT, Chaturvedi SA, Liranso T, Odebo O, Kosheleff AR, Fry N, Cutler AJ, Rubin J, Schwabe S, Childress A. Nasser A, et al. Among authors: rubin j. CNS Drugs. 2022 Aug;36(8):897-915. doi: 10.1007/s40263-022-00938-w. Epub 2022 Jul 27. CNS Drugs. 2022. PMID: 35896943 Free PMC article. Clinical Trial.
Authors' Reply to Singh and Balasundaram: Comment on "A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder".
Nasser A, Hull JT, Liranso T, Fry N, Cutler AJ, Rubin J, Childress A. Nasser A, et al. Among authors: rubin j. CNS Drugs. 2022 Dec;36(12):1333-1335. doi: 10.1007/s40263-022-00967-5. Epub 2022 Nov 4. CNS Drugs. 2022. PMID: 36331781 Free PMC article. Clinical Trial. No abstract available.
2,507 results